ALX Oncology Holdings Inc. (ALXO) Earnings Call Transcripts
ALX Oncology Holdings Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, ALX Oncology Holdings Inc. reported significant advancements in its clinical trials, particularly with evorpacept and zanidatamab for HER2-positive metastatic breast cancer. The company highlighted a 33% objective response rate in heavily pretreated patients, with a median duration of response of 20 months and a median progression-free survival of 22 months for those with high CD47 expression. Management maintained a positive outlook, emphasizing the potential for these therapies to address unmet needs in the oncology market, while also strengthening their balance sheet through recent financing efforts.
Reported metrics
| Metric | Value |
|---|---|
| Objective Response Rate | 33% (beat) |
| Median Duration of Response | 20 months (positive) |
| Median Progression-Free Survival | 22 months (positive) |
| Number of Patients in Study | 24 (neutral) |
| Initial Safety Readout for ALX2004 | Second half of 2026 (neutral) |
| Market Opportunity | $2 billion to $4 billion (positive) |
Guidance from management
Management maintained a positive outlook, signaling confidence in achieving significant data readouts from ongoing trials within the next 12 to 18 months, particularly from the ASPEN-09 trial expected in mid-2027.
What management said
Great. Thanks, Kyle. Appreciate the question. So yes, on the first one, and I'll let Barb weigh in as well. I think we've been very pleased with enrollment to date on our breast study. It's going quite well. Certainly, this data, which we've been able to share just over the last couple of months with the investigators has furthered that enthusiasm. So I think as Barb highlighted well in her comments, feel very good a...
No, go ahead, Barb. I just -- I mean, to kick that off, I mean, I think, of course, we're not going to power the study at 100% ORR, and that's not what we're going to do. And I think -- but if you look at the beauty of a targeted approach, I think it allows and our hope is it will allow a much more targeted Phase III where we can run a tighter registrational study with assumptions that I think are reflective of what ...
What analysts pressed on
Analysts expressed concerns regarding the potential for accelerated approval based on the ASPEN-09 trial results, noting the high bar for regulatory acceptance. Additionally, there were questions about the optimal CD47 expression cut-off for patient selection in future studies.
Main topics on the call
- Evorpacept and Zanidatamab Data — The latest data presented at ESMO Breast 2026 showed a 33% objective response rate in 24 heavily pretreated HER2-positive patients, with a median duration of response of 20 months. Notably, 'all patients who were confirm...
- Progress on ALX2004 — Management reported ongoing progress in the Phase I trial of ALX2004, an EGFR-targeted ADC, which is on track for an initial safety readout in the second half of 2026. The drug is designed to minimize off-tumor toxicity,...
- Financial Position — The company completed a strong financing round in February, which 'further strengthens the balance sheet and enables us to execute through these important data milestones.' This financial stability is crucial for advanci...
- Management's Future Guidance — Management expressed confidence in achieving significant data readouts from ongoing trials within the next 12 to 18 months, indicating a strong pipeline and commitment to advancing both Evo and ALX2004.
Read the full ALX Oncology Holdings Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning November 19, 2020 to May 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 ALX Oncology Holdings Inc. earnings call transcripts on record, spanning November 19, 2020 to May 8, 2026. Based on this history, ALX Oncology Holdings Inc. reports quarterly. The most recent call on file is dated May 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ALXO
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- November 19, 2020
- Most recent
- May 8, 2026
- Reporting cadence
- quarterly